Industry and Technology Minister Mustafa Varank volunteered in the first human trials of the VLP vaccine candidate based on virus-like particles, one of the most innovative vaccine methods developed against Covid-19.
Covidien Turkey TUBITAK-19 Platform-based VLP vaccine candidate time working under the umbrella of the Ministers participating in the Phase 1 stage Varank first dose of vaccine was administered in Ankara Oncology Hospital.
TESTS MADE FIRST
Varank, President of TÜBİTAK Prof. Dr. He came to the hospital's Phase 1 Clinical Research Center in the morning with Hasan Mandal. Ankara Oncology Training and Research Hospital Chief Physician Prof. Dr. Fevzi Altuntaş and Clinical Research Center Coordinator Assoc. Dr. Halil Kara was accompanied. The first dose of the vaccine candidate was administered to Varank, whose blood tests and clinical parameters including ECG were monitored.
21 DOSE AFTER 2 DAYS
Ministers Varank the first dose of the vaccine which was introduced in Turkey in contrast, was not made under the skin into the muscle from the arm by subcutaneous injection method. Varank, who will spend the night in the hospital, is expected to be discharged tomorrow. Varank will receive the second dose of vaccine after 21 days.
INNOVATIVE VACCINE TECHNOLOGY
Varank, said in a statement after the vaccine, the VLP Turkey and stated that an innovative vaccine technology in the world, spoke last year to TUBITAK Covidien-19 Turkey Platform as what to do in the fight against the virus in the country by meeting with professors who all vaccines and drugs work in Turkey they reminded me.
WE FULFILL OUR VOLUNTEERING PROMISE
A teacher told them, "Dear Minister, you support us, open our way, let's produce our vaccine, we will be made ourselves first." Varank said, “We made a promise with Hasan Hodja, as long as our scientists come to the point of producing the vaccine, we will volunteer with you. Today we are fulfilling our volunteer promise. " used the expression.
INNOVATIVE VACCINE CANDIDATE
Emphasizing that the VLP vaccine is an innovative vaccine type in the world, Varank said, “According to the World Health Organization list, there are 4 vaccine candidates that have passed the clinical stages in the world. Here, this vaccine developed by our İhsan and Mayda teachers has different features than those in the world. Our vaccine candidate is a vaccine candidate designed taking into account all 4 proteins of the virus. There are also adjuvants used in vaccines that increase their effectiveness. There is a CpG adjuvant that İhsan Hodja participated in his work in the USA at the beginning. We believe it is an innovative vaccine candidate. We believe that the results will be very different and more effective than those in the world. " he spoke.
DOMESTIC AND NATIONAL
Phase 1 volunteer Varank pointing to the importance of being expressed not much to do in the vaccine Phase 1 study in Turkey. Varank, addressing the citizens who will have vaccination, said, “If it is time for vaccination, if you are committed to vaccination, have the vaccinations applied by our Ministry of Health. But if you want to volunteer in local vaccine studies, don't hesitate. Here, we volunteered for the first human trials in Phase-1 with our Hoca Hasan, and got our vaccine. We want to get this working with Turkey on a new technology called VLP vaccines in recent years by moving quickly to complete Phase 3 study of Turkey's domestic and national VLP vaccine in our hands. Not only in Turkey but also have the benefit of all mankind, but we also want to get the benefit of all humanity. " said.
THE WORLD WILL BE HEALED
Varank said that they will continue to increase the number of centers where Phase-1 trials are carried out together with the Ministry of Health and said, “We are very confident in our virus-like particulate vaccine candidate. If we can find enough volunteers by the end of the year, we will quickly complete Phase-3 and take over our vaccine, and we will have created a successful vaccine that will heal the world. " He spoke in the form.
WE WILL TRY FOR BRITISH MUTATION IN PHASE-2
Stating that the design and design of new mutations can be changed because the technology of virus-like particles is an innovative technology, Varank said, “Currently, our Ihsan and Mayda teachers have made the second design of the VLP vaccine for the British mutation. Animal experiments started now at TÜBİTAK MAM. When the transition to Phase-2 of this vaccine, the design against the British mutation will be tested. Synthetic biology is currently on the agenda as the prominent branch of science in the world. Interest in him will increase in the upcoming period. Studies on this technology will increase. One of the important features of synthetic biology is its ability to adapt quickly. The VLP vaccine will be tested for the British mutation in Phase-2. But it is possible to develop a new species for other mutations very quickly, our teachers are working on this.
CALL FROM MANDAL TO "BE A VOLUNTEER"
TÜBİTAK President Prof. Dr. Hasan Mandal, March 27, 2021 stating that VLP vaccine in Phase 1 stage of transition, "Turkey is not a country that develops produces the following science and technology. I wish this will be beneficial for our country. I recommend all of our people and students to volunteer. I thank those who contributed to the process. " said.
ALTUNTAŞ: "WE WILL GO TO PHASE-4 AS OF MAY 2"
Ankara Oncology Training and Research Hospital Chief Physician Prof. Dr. Drawing attention to the completion of the first dosing of the vaccine, Fevzi Altuntaş said, “We have completed the Phase-36 VLP study on 1 volunteers. We will have started Phase-4 studies of our vaccine as of May 2. We will have completed the phase studies of our local vaccine as soon as possible. " used the expression.
36 PEOPLE PARTICIPATE IN HUMAN TRIALS
Prof. Dr. Human trials of the VLP vaccine candidate, developed as a result of the joint project of Mayda Gürsel and Bilkent University İhsan Gürsel couple, are applied to two groups of 18 plus 18, one low and one high dose. Six of each group consists of placebo, that is, injections that do not contain an active or active substance.
THERE ARE 36 MORE VOLUNTEERS
The names of 36 volunteers, except for Varank and the President of TÜBİTAK Mandal, are kept secret. The healthcare personnel administering the vaccine cannot have information about the content of the injection in the person being administered.
THE 4th VACCINE CANDIDATE IN THE CLINICAL STAGE
World No. TÜBİTAK Covidien-19 Turkey Platform covered by the vaccine candidate developed with a single VLP technology, taking place in the WHO Covidien-30 vaccine candidates list March 19 clinical stage this kind in the world was the 4th vaccine candidate.